ArticleAnnals of the rheumatic diseases2019
Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus.
Open access · hybridAbstract read
In one paragraph
Article in Annals of the rheumatic diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Role of the PADI family in inflammatory autoimmune diseases and cancers: A systematic review.Frontiers in immunology · 2023Pooled it
- Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.Nature communications · 2021Trial
- Hepatic control of immunometabolism: implications for the pathogenesis, diagnosis and treatment of rheumatic diseases.Nature reviews. Rheumatology · 2026Review
- Review
- Epigenetic regulatory mechanisms of autoimmune skin diseases: novel biomarkers and therapeutic prospects.Clinical epigenetics · 2025Review
- Prenatal exposure to Zika virus shapes offspring neutrophil function in a sex-specific manner.Nature communications · 2025Article
- The emerging role of neutrophil extracellular traps in autoimmune and autoinflammatory diseases.MedComm · 2025Review
- CRISPR-Cas9 editing ofFrontiers in genome editing · 2025Article
- CD93: A Promising NETs-Related Biomarker for Diagnosis and Therapy in Actinic Keratosis.OncoTargets and therapy · 2025Article
- Review
- Single-cell dissection reveals immunosuppressive F13A1+ macrophage as a hallmark for multiple primary lung cancers.Clinical and translational medicine · 2024Article
- Systemic lupus erythematosus: pathogenesis and targeted therapy.Molecular biomedicine · 2024Review
- A Multilayered Post-Genome-Wide Association Study Analysis Pipeline Defines Functional Variants and Target Genes for Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Inhibition of NLRP3 inflammasome activation by A20 through modulation of NEK7.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- A20 in Kidney Transplantation and Autoimmunity.International journal of molecular sciences · 2024Review
- The Complexity of Being A20: From Biological Functions to Genetic Associations.Journal of clinical immunology · 2024Review
- Article
- Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy.Frontiers in genetics · 2024Review
- Gastric cancer secreted miR-214-3p inhibits the anti-angiogenesis effect of apatinib by suppressing ferroptosis in vascular endothelial cells.Oncology research · 2024Article
- Recent advances in the role of neutrophils and neutrophil extracellular traps in acute pancreatitis.Clinical and experimental medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 8 institutions in 4 countries.
Lina OdqvistResearch and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.ORCID 0000-0001-6002-0968
Zala Jevnikar *Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.
Rebecca Riise *Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.
Lisa ÖbergResearch and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.
Magdalena RhedinResearch and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.
Dag LeonardDepartment of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.
Linda YrlidResearch and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.
Sonya JacksonResearch and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.
Johan MattssonResearch and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.
Sambit NandaMRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.
Philip CohenMRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.
Axel KnebelMRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.
Simon ArthurDivision of Immunology and Cell Signaling, School of Life Sciences, University of Dundee, Dundee, UK.
Kristofer ThörnResearch and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.
Elisabet SvenungssonDepartment of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden.
Andreas JönsenSkåne University Hospital, Department of Clinical Science Lund, Rheumatology, Lund University, Lund, Sweden.
Iva GunnarssonDepartment of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden.
Karolina TandreDepartment of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.
Andrei AlexssonDepartment of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.
Alf KastbomDepartment of Rheumatology and Department of Clinical and Experimental Medicine, Linköping University, Linkoping, Sweden.
Solbritt Rantapää-DahlqvistDepartment of Public Health and Clinical Medicine/Rheumatology, Umeå Universitet Medicinska fakulteten, Umea, Sweden.
Maija-Leena ElorantaDepartment of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.
Ann-Christine SyvänenDepartment of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.
Anders BengtssonSkåne University Hospital, Department of Clinical Science Lund, Rheumatology, Lund University, Lund, Sweden.
Patrik JohanssonDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.
Johanna K SandlingDepartment of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.
Christopher SjöwallDepartment of Rheumatology and Department of Clinical and Experimental Medicine, Linköping University, Linkoping, Sweden.ORCID 0000-0003-0900-2048
Lars RönnblomDepartment of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.
Barry CollinsResearch and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.
Outi VaaralaResearch and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden vaaralao@medimmune.com.
AstraZeneca (Sweden) · SEUppsala University · SEUniversity of Dundee · GBKarolinska Institutet · SELinköping University · SELund University · SEAstraZeneca (Netherlands) · NLUmeå University · SE
Funding
Medical Research Council MRC000985Medical Research Council MR/R021406/1Wellcome Trust 209380/Z/17/Z
Abstract
objectivesGenetic variations in
methodsCRISPR/Cas9 was used to generate human U937 monocytes with A20 DUB-inactivating
resultsGenetic disruption of A20 DUB domain in human and murine myeloid cells did not give rise to enhanced NF-κB signalling. Instead, cells with
conclusionsWe propose that genetic alterations disrupting the A20 DUB domain mediate increased susceptibility to SLE through the upregulation of
Indexed as
AnimalsAutoantibodiesCitrullinationEndopeptidasesEpitopesExtracellular TrapsGenetic Predisposition to DiseaseHumansLupus Erythematosus, SystemicMiceNeutrophilsNF-kappa BPolymorphism, GeneticProtein-Arginine Deiminase Type 4Tumor Necrosis Factor alpha-Induced Protein 3Up-RegulationAutoantibodiesEndopeptidasesEpitopesNF-kappa BProtein-Arginine Deiminase Type 4Tumor Necrosis Factor alpha-Induced Protein 3ubiquitin isopeptidaseNETPAD4PADI4peptidyl arginine deiminasers2230926
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.